266 related articles for article (PubMed ID: 17223085)
1. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial.
Lee AM; Jepson C; Hoffmann E; Epstein L; Hawk LW; Lerman C; Tyndale RF
Biol Psychiatry; 2007 Sep; 62(6):635-41. PubMed ID: 17223085
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation.
David SP; Brown RA; Papandonatos GD; Kahler CW; Lloyd-Richardson EE; Munafò MR; Shields PG; Lerman C; Strong D; McCaffery J; Niaura R
Nicotine Tob Res; 2007 Aug; 9(8):821-33. PubMed ID: 17654295
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic investigation of smoking cessation treatment.
Lerman C; Shields PG; Wileyto EP; Audrain J; Pinto A; Hawk L; Krishnan S; Niaura R; Epstein L
Pharmacogenetics; 2002 Nov; 12(8):627-34. PubMed ID: 12439223
[TBL] [Abstract][Full Text] [Related]
4. Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data.
Cox LS; Faseru B; Mayo MS; Krebill R; Snow TS; Bronars CA; Nollen NL; Choi WS; Okuyemi KS; Salzman GA; Benowitz NL; Tyndale RF; Ahluwalia JS
Trials; 2011 Jan; 12():22. PubMed ID: 21266057
[TBL] [Abstract][Full Text] [Related]
5. Determinants of the rate of nicotine metabolism and effects on smoking behavior.
Johnstone E; Benowitz N; Cargill A; Jacob R; Hinks L; Day I; Murphy M; Walton R
Clin Pharmacol Ther; 2006 Oct; 80(4):319-30. PubMed ID: 17015050
[TBL] [Abstract][Full Text] [Related]
6. CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy.
Tomaz PR; Santos JR; Issa JS; Abe TO; Gaya PV; Krieger JE; Pereira AC; Santos PC
Eur J Clin Pharmacol; 2015 Sep; 71(9):1067-73. PubMed ID: 26153084
[TBL] [Abstract][Full Text] [Related]
7. Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism.
Ring HZ; Valdes AM; Nishita DM; Prasad S; Jacob P; Tyndale RF; Swan GE; Benowitz NL
Pharmacogenet Genomics; 2007 Dec; 17(12):1007-15. PubMed ID: 18004205
[TBL] [Abstract][Full Text] [Related]
8. CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion.
Zhu AZ; Cox LS; Nollen N; Faseru B; Okuyemi KS; Ahluwalia JS; Benowitz NL; Tyndale RF
Clin Pharmacol Ther; 2012 Dec; 92(6):771-7. PubMed ID: 23149928
[TBL] [Abstract][Full Text] [Related]
9. The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans.
Ilic K; Hawke RL; Thirumaran RK; Schuetz EG; Hull JH; Kashuba AD; Stewart PW; Lindley CM; Chen ML
Drug Metab Dispos; 2013 Mar; 41(3):575-81. PubMed ID: 23238783
[TBL] [Abstract][Full Text] [Related]
10. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials.
Lerman C; Jepson C; Wileyto EP; Epstein LH; Rukstalis M; Patterson F; Kaufmann V; Restine S; Hawk L; Niaura R; Berrettini W
Neuropsychopharmacology; 2006 Jan; 31(1):231-42. PubMed ID: 16123753
[TBL] [Abstract][Full Text] [Related]
11. Genetic variants in the serotonin transporter influence the efficacy of bupropion and nortriptyline in smoking cessation.
Quaak M; van Schayck CP; Postma DS; Wagena EJ; van Schooten FJ
Addiction; 2012 Jan; 107(1):178-87. PubMed ID: 21658141
[TBL] [Abstract][Full Text] [Related]
12. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects.
Robertson SM; Maldarelli F; Natarajan V; Formentini E; Alfaro RM; Penzak SR
J Acquir Immune Defic Syndr; 2008 Dec; 49(5):513-9. PubMed ID: 18989234
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes.
Hesse LM; He P; Krishnaswamy S; Hao Q; Hogan K; von Moltke LL; Greenblatt DJ; Court MH
Pharmacogenetics; 2004 Apr; 14(4):225-38. PubMed ID: 15083067
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial.
Aubin HJ; Lebargy F; Berlin I; Bidaut-Mazel C; Chemali-Hudry J; Lagrue G
Addiction; 2004 Sep; 99(9):1206-18. PubMed ID: 15317642
[TBL] [Abstract][Full Text] [Related]
15. Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment.
Lee AM; Tyndale RF
J Psychopharmacol; 2006 Jul; 20(4 Suppl):7-14. PubMed ID: 16785264
[TBL] [Abstract][Full Text] [Related]
16. Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence.
Berrettini WH; Wileyto EP; Epstein L; Restine S; Hawk L; Shields P; Niaura R; Lerman C
Biol Psychiatry; 2007 Jan; 61(1):111-8. PubMed ID: 16876132
[TBL] [Abstract][Full Text] [Related]
17. Are serotonergic system genes associated to smoking cessation therapy success in addition to CYP2A6?
Verde Z; Santiago C; Rodríguez González-Moro JM; de Lucas Ramos P; López Martín S; Bandrés F; Lucia A; Gómez-Gallego F
Pharmacopsychiatry; 2014 Jan; 47(1):33-6. PubMed ID: 24127329
[TBL] [Abstract][Full Text] [Related]
18. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain.
Miksys S; Lerman C; Shields PG; Mash DC; Tyndale RF
Neuropharmacology; 2003 Jul; 45(1):122-32. PubMed ID: 12814665
[TBL] [Abstract][Full Text] [Related]
19. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6.
Mo SL; Liu YH; Duan W; Wei MQ; Kanwar JR; Zhou SF
Curr Drug Metab; 2009 Sep; 10(7):730-53. PubMed ID: 19702527
[TBL] [Abstract][Full Text] [Related]
20. Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6).
Chen LS; Bloom AJ; Baker TB; Smith SS; Piper ME; Martinez M; Saccone N; Hatsukami D; Goate A; Bierut L
Addiction; 2014 Jan; 109(1):128-137. PubMed ID: 24033696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
